Suchergebnisse - "Cui, Xuewei"

PubPharm (5)

1

Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM : A Randomized, Placebo-Controlled, Phase I Study

enthalten in: Advances in therapy | 2022

von Xu, J. | Zhang, Y. | Li, Y. | +7

2

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes : a randomised, placebo-controlled and active comparator-controlled phase 2 trial

enthalten in: Lancet (London, England) | 2018

von Frias, J. | Nauck, M. | Van, J. | +8

CommentIn: Lancet. 2018 Nov 17;392(10160):2142-2144. - PMID 30293768

3

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

enthalten in: Clinical pharmacokinetics | 2017

von de la Peña, A. | Cui, X. | Geiser, J. | +1

4

Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion

enthalten in: Diabetes, obesity & metabolism | 2017

von de la Peña, A. | Loghin, C. | Cui, X. | +3

5

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes : Analyses of Data from Clinical Trials

enthalten in: Clinical pharmacokinetics | 2016

von Geiser, J. | Heathman, M. | Cui, X. | +4

1
[1]